Multicenter, phase III, randomized, blinded, controlled, parallel group.
This is a 24-week, multicenter, phase III, randomized, blinded, controlled, parallel group with a 24-week treatment period to evaluate the efficacy and safety of LYR-210 compared with sham control for treatment in adults with CRS.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
182
LYR-210 drug matrix (mometasone furoate)
Sham procedure control
Daily Saline Irrigation
Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps
The 3CS are nasal blockage/obstruction/congestion, anterior/posterior nasal discharge, and facial pain/pressure. The diary is completed daily by study participants throughout the study. Each symptom is rated on a 4-point (0-3) scale where 0= none/absent symptoms, 1=mild symptoms, 2=moderate symptoms, and 3=severe symptoms. The composite score of 3CS is the sum of the three cardinal symptom scores. The 3CS total score ranges from 0-9, with higher scores indicating worse symptoms.
Time frame: Week 24
CFBL in the 7-day Average Composite Score of 3CS in All Participants at Week 24
The 3CS are nasal blockage/obstruction/congestion, anterior/posterior nasal discharge, and facial pain/pressure. The diary is completed daily by study participants throughout the study. Each symptom is rated on a 4-point (0-3) scale where 0= none/absent symptoms, 1=mild symptoms, 2=moderate symptoms, and 3=severe symptoms. The composite score of 3CS is the sum of the three cardinal symptom scores. The 3CS total score ranges from 0-9, with higher scores indicating worse symptoms.
Time frame: Week 24
CFBL in the 22-item Sino-Nasal Outcome Test (SNOT-22) Total Score at Week 24
The SNOT-22 questionnaire is a 22-item disease-specific quality of life instrument. Each symptom is scored on a 6-point scale where 0 = no problem and 5 = problem as bad as it can be. The total SNOT-22 score is the sum of the 22 items and can range from 0 to 110 with higher scores indicating worse symptoms.
Time frame: Week 24
CFBL in the 3-D Volumetric CT Score at Week 20
Change from baseline in the percent opacification of the bilateral anterior and posterior ethmoids at Week 20, as determined by 3-D volumetric CT analysis. 3-D volumetric scoring involves evaluations of each slice of 3-D coronal CT sequences and summing of all the slices to create a volumetric score ranging from 0% to 100%. A negative change from Baseline indicates improvement from Baseline.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Novak Clinical Trials
Tucson, Arizona, United States
Keck School of Medicine at USC Medical Center
Arcadia, California, United States
Sensa Health Clinical Research
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of California - Irvine Medical Center
Orange, California, United States
Sacramento Ear Nose and Throat Surgical and Medical Group, Inc
Roseville, California, United States
University of California - Davis
Sacramento, California, United States
Regional Head & Neck Consulting - SENTA Clinic
San Diego, California, United States
Breathe Clear Institute
Torrance, California, United States
Colorado ENT and Allergy
Colorado Springs, Colorado, United States
...and 47 more locations
Time frame: Week 20
Rescue Treatment Requirement Through Week 24
Number and percent of participants requiring rescue treatment (systemic corticosteroid for any reason or participants that were recommended/underwent sinonasal surgery) through Week 24.
Time frame: Week 24